-
Abstract Number: PB1900
Observational Study of Outcomes in Patients with Antiphospholipid Syndrome Anticoagulated with Rivaroxaban
-
Abstract Number: PB1894
Obstetric Antiphospholipid Syndrome: ADAMTS-13 Tested at Pregnancy Diagnosis Is Associated with the Occurrence of Early-Onset Pre-Eclampsia Despite Treatment
-
Abstract Number: PB1856
Oligosymptomatic Thrombosis in a Young Girl with Upshaw-Schulman Syndrome (USS) Not Receiving Prophylactic Plama Infusion
-
Abstract Number: PB1667
Omega-3 Fatty Acids Significantly Improve the Antiplatelet Profile of Triflusal
-
Abstract Number: PB1763
Omega-6 DPA and its 12-LOX Oxylipins Regulate Platelet Reactivity in a Non-genomic PPARa-dependent Manner
-
Abstract Number: PB0699
On the Measurement of Direct Anti-Xa-Inhibitors
-
Abstract Number: PB0963
One-Stage versus Chromogenic Factor IX Activity in Haemophilia B
-
Abstract Number: PB0747
Online Apps Improve Haemostasis Assay Reproducibility and Facilitate Open Data and Code Sharing
-
Abstract Number: PB0245
ONO-1600586, an Oral Direct Factor XIa Inhibitor, Suppresses Thrombus Formation in Rabbit Jugular Vein without Bleeding Tendency
-
Abstract Number: PB0161
Operational Feasibility of a Pharmacist-Guided Personalized Medicine Consult Service for Warfarin in Mandatory and Optional Testing Settings
-
Abstract Number: PB2489
Optimal Duration and Dose Intensity of the Anticoagulation Therapy with Doacs in Venous Thromboembolism: Retrospective, Cohort Study “Real Choice”
-
Abstract Number: PB0202
Optimisation of Assays for Laboratory Monitoring of Emicizumab in Treated Patients
-
Abstract Number: PB1967
Optimization of Disease- and Patient-specific in vitro Assays for Endothelial Dysfunction Investigation by Using Endothelial Colony-forming Cells
-
Abstract Number: PB1151
Optimization of Measurement of Emicizumab, FVIII and Anti-FVIII Activity in Patients Treated with Emicizumab
-
Abstract Number: PB2266
Optimizing Magnetic Resonance Direct Thrombus Imaging for Differentiating Acute from Chronic Splanchnic Vein Thrombosis
-
Abstract Number: PB1158
Optimizing Outcomes in Hemophilia A Prophylaxis Using Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc): Results from Three Portuguese Haemophilia Centers
-
Abstract Number: PB2573
Optimizing Tranexamic Acid Dosing for Hemorrhage Prevention in Pregnant Women
-
Abstract Number: PB/LB06
Oral Anticoagulation in Elderly Patients with Atrial Fibrillation: The Murcia AF Project Phase II
-
Abstract Number: PB2462
Oral Anticoagulation Therapy for Venous Thromboembolism in Norway: Patient Characteristics, Treatment Trends and Patterns
-
Abstract Number: PB2494
Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk
-
Abstract Number: OC 11.1
Outcome of DOAC Exposure during Pregnancy (…and the Problem of Event Reporting…)
-
Abstract Number: PB1337
Outcome of Splenectomy in Adult Refractory Immune Thrombocytopenic Purpura – A Descriptive Analysis
-
Abstract Number: PB2275
Outcome of the Symptomatic Subsegmental Isolated Pulmonary Embolism: The SSPE Padua Study
-
Abstract Number: PB2551
Outcomes in Women with Mechanical Heart Valves Anticoagulated with Low Molecular Weight Heparin During Pregnancy
-
Abstract Number: PB0304
Outcomes of Patients with Anti-Xa versus APTTr Monitoring for Unfractionated Heparin Infusions during Extracorporeal Membrane Oxygenation
-
Abstract Number: PB2441
Outcomes of the First Australian Pulmonary Embolism Response Team (PERT) Model of Care for Intermediate to High Risk Pulmonary Embolism
-
Abstract Number: OC 06.1
OvCa-Chip: A New Organ-on-a-Chip Experimental Model to Dissect Platelet & Vascular (dys)Function in Ovarian Cancer
-
Abstract Number: PB0489
Overdosing of Protamine during Cardiopulmonary Bypass May Increase Use of Unnecessary Blood Product Administration when Monitoring with ROTEM
-
Abstract Number: PB0061
Overexpression of FXII as a Risk of Thrombosis in Patients with SAMTER Syndrome, Angioneurotic Edema, and its Association with Smoking Rate and Hematological Parameters
ISTH 2020 Congress
July 12-14, 2020. Virtual Congress.